Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043236 | 0.95 | SIRT6 (0.50) | MAPTTP53CACNA1GSIRT6DRD2 | |
| SCHEMBL12043264 | 0.94 | SIRT6 (0.50) | MAPTTP53CACNA1GSIRT6DRD2 | |
| SCHEMBL12043268 | 0.93 | SIRT6 (0.51) | CACNA1GSIRT6DRD2DRD3HTR1A | |
| SCHEMBL12043269 | 0.91 | SIRT6 (0.47) | CACNA1GSIRT6DRD2DRD3HTR1A | |
| SCHEMBL9984436 | 0.89 | SIRT6 (0.51) | SIRT6DRD2DRD3HTR1AHTR7 | |
| SCHEMBL12043295 | 0.89 | SIRT6 (0.52) | MAPTCACNA1GSIRT6DRD2DRD3 | |
| SCHEMBL12043238 | 0.88 | SIRT6 (0.52) | MAPTTP53CACNA1GSIRT6DRD2 | |
| SCHEMBL12043237 | 0.88 | SIRT6 (0.53) | MAPTSIRT6DRD2DRD3HTR1A | |
| SCHEMBL12059676 | 0.87 | SIRT6 (0.51) | MAPTSIRT6DRD2HTR1AHTR7 | |
| SCHEMBL12059471 | 0.86 | SIRT6 (0.50) | MAPTCACNA1GSIRT6DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | MAPT 1648/4885TP53 4065/4885CACNA1G 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.